Kindred Biosciences, Inc. (KIN): Price and Financial Metrics
KIN Price/Volume Stats
| Current price | $9.25 | 52-week high | $9.28 |
| Prev. close | $9.24 | 52-week low | $3.46 |
| Day low | $9.24 | Volume | 178,400 |
| Day high | $9.26 | Avg. volume | 840,890 |
| 50-day MA | $9.19 | Dividend yield | N/A |
| 200-day MA | $5.89 | Market Cap | 420.52M |
KIN Stock Price Chart Interactive Chart >
Kindred Biosciences, Inc. (KIN) Company Bio
Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The companys product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company was founded in 2012 and is based in Burlingame, California.
Latest KIN News From Around the Web
Below are the latest news stories about Kindred Biosciences Inc that investors may wish to consider to help them evaluate KIN as an investment opportunity.
INVESTIGATION: Halper Sadeh LLP Investigates SYKE, MCF, ONEM, KIN; Shareholders are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / August 17, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Sykes Enterprises, Incorporated (NASDAQ:SYKE)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sitel Group for $54. If you are a Sykes shareholder, click here to learn more about your rights and options. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds KIN, SYKE, MNR, and QTS Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER ALERT: Monteverde & Associates PC Continues to Investigate the Following MergerNEW YORK, NY / ACCESSWIRE / August 16, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Kindred Biosciences, Inc. (NASDAQ:KIN) relating to its proposed acquisition by Elanco Animal Health, Inc. |
INVESTIGATION: Halper Sadeh LLP Investigates BRBS, KIN, MNR, IKNX; Shareholders are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / August 11, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Blue Ridge Bankshares, Inc. (NYSE American:BRBS)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with FVCBankcorp, Inc. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds SQ, TBIO, KIN, and MNR Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
KIN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 84.26% |
| 5-year | 0.98% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | -49.17% |
| 2019 | -22.56% |
Continue Researching KIN
Want to do more research on Kindred Biosciences Inc's stock and its price? Try the links below:Kindred Biosciences Inc (KIN) Stock Price | Nasdaq
Kindred Biosciences Inc (KIN) Stock Quote, History and News - Yahoo Finance
Kindred Biosciences Inc (KIN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...